Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our study identifies miR-146a as an important molecular brake that blocks the autocrine IL-6- and IL-21-induced Th17 differentiation pathways in autoreactive CD4 T cells, highlighting its potential as a therapeutic target for treating autoimmune diseases.
|
28872459 |
2017 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-22 provides a new insight into the mechanisms of autoimmunity, and copy number variations (CNVs) are associated with autoimmune diseases.
|
28716697 |
2017 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our work provides mechanistic insight into the contribution of IL-21 to the pathogenesis of murine lupus, while revealing the importance of T-B cellular cross-talk in mediating autoimmunity, demonstrating that its interruption impacts both cell types leading to disease amelioration.
|
28219887 |
2017 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, SFN significantly inhibited the activation of untransformed human T-cells derived from healthy donors or RA patients, and downregulated the expression of the transcription factor RORγt, and the T<sub>H</sub>17-related cytokines IL-17A, IL-17F, and IL-22, which play a major role within the pathophysiology of many chronic inflammatory/autoimmune diseases.
|
30487791 |
2018 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the early studies on IL-17 focused on Th17 cells, it was later demonstrated that γδ T cells were an important early source of IL-17 and IL-21 that helped amplify IL-17 production by Th17 cells in autoimmune diseases.
|
29395738 |
2018 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-22 is one of the member of IL-10 cytokine family, and several studies have implicated IL-22 signaling in the pathogenesis of autoimmune diseases.
|
29336866 |
2018 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-22, a potent target for treatment of non-autoimmune diseases.
|
30335564 |
2018 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical significance and immunobiology of IL-21 in autoimmunity.
|
30773373 |
2019 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasma cytokine analysis confirms elevation of multiple autoimmunity-related cytokines (e.g., TNF-α, IL17A-D, IL-22) in people with DS, independent of diagnosis of autoimmunity.
|
31699819 |
2019 |
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients who have developed autoimmunity also show a high basal level of IL-21, a cytokine which increases the growth of auto-reactive T-cells.
|
31371976 |
2019 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This study therefore elucidates critical mechanism for IL-21-induced Th17 differentiation to indicate SKI and SMAD4 as potential therapeutic targets for treating autoimmune diseases.
|
31398665 |
2019 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-21 is a pleiotropic cytokine that plays a key role in modulating inflammatory responses, including the promotion of autoimmune diseases.
|
30590020 |
2019 |
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin 22 ameliorates neuropathology and protects from central nervous system autoimmunity.
|
31080013 |
2019 |